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Abstract 
Cancer cells can acquire a spectrum of stable hybrid epithelial/mesenchymal (E/M) states during 
epithelial-mesenchymal transition (EMT). Cells in these hybrid E/M phenotypes often combine 
epithelial and mesenchymal features and tend to migrate collectively commonly as small clusters. 
Such collectively migrating cancer cells play a pivotal role in seeding metastases and their presence 
in cancer patients indicates an adverse prognostic factor. Moreover, cancer cells in hybrid E/M 
phenotypes tend to be more associated with stemness which endows them with tumor-initiation 
ability and therapy resistance. Most recently, cells undergoing EMT have been shown to promote 
immune suppression for better survival. A systematic understanding of the emergence of hybrid 
E/M phenotypes and the connection of EMT with stemness and immune suppression would 
contribute to more effective therapeutic strategies. In this review, we first discuss recent efforts 
combining theoretical and experimental approaches to elucidate mechanisms underlying EMT 
multi-stability (i.e. the existence of multiple stable phenotypes during EMT) and the properties of 
hybrid E/M phenotypes. Following we discuss non-cell-autonomous regulation of EMT by cell 
cooperation and extracellular matrix. Afterwards, we discuss various metrics that can be used to 
quantify EMT spectrum. We further describe possible mechanisms underlying the formation of 
clusters of circulating tumor cells. Last but not least, we summarize recent systems biology 
analysis of the role of EMT in the acquisition of stemness and immune suppression.  
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Introduction 
Metastasis remains the major cause of cancer-related deaths [1]. To enable successful metastasis, 
cancer cells often engage a trans-differentiation program referred to as epithelial-mesenchymal 
transition (EMT) in order to promote migratory and invasive properties [2]. During EMT, cells 
gradually lose epithelial features such as a cobblestone-like morphology, cell-cell adhesion and 
apico-basal polarity and acquire mesenchymal features such as a spindle-like morphology, 
increased motility and invasiveness [2]. The concept of EMT was initially described during 
embryonic development. EMT was first observed in vitro by Greenberg and Hay showing that 
epithelial cells suspended in three-dimensional collagen gels lose their apical-basal polarity and 
acquire characteristics of migrating mesenchymal cells [3]. Later in vivo work by Nieto et al. 
argued that EMT is essential for the formation of mesoderm and the generation of the migratory 
neutral crest cells during chicken embryonic development [4]. EMT also plays a critical role during 
physiological wound repair and pathological fibrosis [5]. In the context of cancer metastasis, EMT 
has been proposed to be typically associated with enhanced metastatic potential of cancer cells [2] 
and the reverse process - mesenchymal-epithelial transition (MET) – has been considered to 
facilitate effective metastatic colonization by regaining epithelial and proliferative traits that are 
lost during EMT [6]. 
 
During metastasis of tumors, cells rarely undergo a complete EMT and enter a fully mesenchymal 
phenotype [7]. Instead, partial EMT leading to a hybrid epithelial/mesenchymal (E/M) phenotype 
has often been observed [8]. In other words, recent studies have emphasized that contrary to the 
prevailing dogma of EMT being a binary process, there exists a spectrum of hybrid E/M 
phenotypes characterized by varying extents of epithelial and mesenchymal features and 
associated with metastatic potential and invasiveness [9,10]. Cancer cells in these hybrid E/M 
phenotypes tend to combine epithelial (e.g. cell-cell adhesion) and mesenchymal (e.g. increase 
motility) traits [11] and can thus migrate collectively as a cluster, which can reach and enter the 
bloodstream intact. Clusters of circulating tumor cells (CTCs) or CTC clusters contribute much 
more than their proportional share to forming metastases relative to individual CTCs which are 
typically mesenchymal cells [12]. Clinical evidence supports the aggressiveness of CTC clusters 
and their presence in the peripheral blood has been shown to be a prognostic factor for poor patient 
survival across multiple types of cancer [13]. Therefore, a better understanding of the mechanisms 
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underlying the emergence of hybrid E/M phenotypes and the formation of CTC clusters can lead 
to more effective therapeutic designs targeting metastasis. 
 
Recently there have been ongoing debates regarding the necessity of EMT for metastasis [14]. 
Zheng et al. demonstrated that deletion of the EMT-inducing transcription factor (EMT-TF) 
SNAIL or TWIST in genetically engineered mouse models of pancreatic ductal adenocarcinoma 
(PDAC) did not cause any significant change in tumor progression and metastasis [15]. Fischer et 
al. suggested that EMT inhibition by over-expression of microRNA (miR)-200 led to no obvious 
change in lung metastasis development in spontaneous breast-to-lung metastasis mouse models 
[16]. From our perspective, these two studies assumed that EMT can be completely repressed by 
single factor manipulation, for example, deletion of SNAIL or TWIST in PDAC or over-
expression of miR-200 in breast cancer. Following these studies, Krebs et al. used the same PDAC 
model [15] and showed that deletion of the EMT-TF ZEB1 significantly suppresses the 
colonization capacity of tumor cells and the formation of metastases [17], indicating a non-
redundant role of EMT-TFs in regulating PDAC metastasis [18]. Moreover, another study by 
Cursons et al. showed that overexpression of miR-200c in the HMLE-derived mesenchymal cells 
established by exposing HMLE cells to TGF-β for 24 days can only drive a partial MET where the 
canonical epithelial marker E-cadherin increases but the mesenchymal maker vimentin remains 
[19]. One major contributing factor to these debates regarding the functional role of EMT in 
metastasis is the lack of consistency in defining EMT itself, owing to its highly nonlinear and 
multidimensional nature [20]. Thus, a rigorous quantification of the EMT status of tumor cells and 
a systematic analysis of the interacting EMT regulators such as interactions between miRNAs, 
EMT-TFs and epigenetic factors is urgently needed. 
 
Notably, various extracellular biochemical and biomechanical factors can govern the induction 
and maintenance of a partial or complete EMT. For instance, neighboring cells can induce EMT 
through TGF-β secretion [21] or Notch signaling [22], and also the alteration of stiffness of 
extracellular matrix (ECM) can trigger EMT [23]. In addition to the complexity of EMT itself, 
cancer cells undergoing EMT tend to acquire “stemness” characteristics, which are believed to be 
responsible for tumor-initiation ability and therapy resistance [24]. Moreover, cancer cells can 
interact with many other types of cells in the tumor microenvironment, such as fibroblasts, 
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endothelial cells and immune cells [25,26]. Specifically, the co-evolution of cancer and immune 
cells [27,28] has captured attentions recently due to the promising effects of cancer 
immunotherapy [29,30]. Because of the typically enhanced metastatic potential and therapy 
resistance of cancer cells undergoing EMT, it is natural to analyze the correlation and causal 
relationship between EMT and immune response [31,32]. Furthermore, both EMT [1,2] and 
immune signatures [33–39] have been shown to be prognostic indicators for various types of 
cancer. A better understanding of their relationship can potentially contribute to more effective 
therapeutic designs. 
 
In this review, we focus on how a combination of theoretical and experimental efforts has led to a 
better understanding of the EMT multi-stability, the characteristics of the hybrid E/M phenotypes 
and the association of EMT with the acquisition of stemness and immune suppression (Figure 1). 
We start with a discussion of mathematical modeling studies of EMT regulatory networks, that 
elucidate mechanisms underlying EMT multi-stability and particularly the emergence of hybrid 
E/M phenotypes. Then we summarize recent in vitro and in vivo experimental studies that 
characterize hybrid E/M phenotypes. We then discuss non-cell-autonomous regulation of EMT by 
cell cooperation and ECM. We further discuss metrics that have been developed to quantify EMT 
status without pre-supposing that cells lie at the extreme ends of completely epithelial or 
completely mesenchymal. Finally, we extend our discussion to the coupling of EMT with stemness 
and immune response.  
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Figure 1. An overview of epithelial-mesenchymal plasticity - causes and consequences. 
Multiple signaling pathways driving EMT/MET tend to converge to a core regulatory circuit which 
involves both transcriptional and post-transcriptional regulation. The core regulatory circuit 
exhibits multi-stable dynamics and govern the transitions between different EMT phenotypes. The 
epithelial-mesenchymal plasticity enables both collective and individual cell invasion and has been 
implicated in multiple processes including avoiding immune destruction and heightened tumor 
initiation. 
 
Emergence of hybrid epithelial/mesenchymal phenotypes 
Hybrid E/M phenotypes are predicted by mathematical modeling of EMT regulation 
EMT is governed by a complex gene regulatory network (GRN) including miRNAs, transcription 
factors (TFs), alternative spicing factors, epigenetic modifiers, growth factors, long non-coding 
RNAs and others [7,40,41]. Several groups have proposed that two microRNA families miR-200 
and miR-34 interacting with two EMT-TF families ZEB and SNAIL tend to form a core EMT 
regulatory network [40]. Many signaling pathways such as TGF-b, WNT and Notch impinge upon 
this network to regulate EMT. The miR-200 and miR-34 function as guardians of the epithelial 
phenotype and ZEB and SNAIL promote EMT. Mechanism-based mathematical modeling of this 
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network that includes a detailed treatment of microRNA-mediated regulation suggests that it can 
give rise to three stable states: an epithelial phenotype characterized by miR-200high/ZEBlow/miR-
34high/SNAILlow; a mesenchymal phenotype characterized by miR-200low/ZEBhigh/miR-
34low/SNAILhigh; and a hybrid E/M phenotype characterized by co-expression of miR-200 and ZEB 
[42]. According to this model, the miR-200/ZEB circuit can function as a three-way decision-
making switch governing the transitions between epithelial, mesenchymal and hybrid E/M 
phenotypes and the miR-34/SNAIL circuit primarily functions as a noise-buffering integrator [42]. 
Alternatively, a different characterization of the hybrid E/M state has been proposed: starting from 
an epithelial state - miR-200high/ZEBlow/miR-34high/SNAILlow, a hybrid state can be achieved when 
the miR-34/SNAIL circuit switches from miR-34high/SNAILlow to miR-34low/SNAILhigh, but the 
miR-200/ZEB circuit is maintained at miR-200high/ZEBlow [43]. Despite these differences [44], 
both of these mathematical models clearly indicate that EMT need not be a binary process and 
instead a stable hybrid E/M state expressing both epithelial and mesenchymal traits can be the end 
point of a transition. 
 
The existence of hybrid E/M states has been further supported by other computational studies 
analyzing extended versions of the core EMT regulatory network [45–47]. Steinway et al. showed 
combinatorial intervention of TGF-β signal and SMAD suppression can lead to multiple hybrid 
E/M states using Boolean modeling [45]. Huang et al. and Font-Clos et al. showed that the hybrid 
E/M phenotypes are robust stable states emerging due to the topologies of EMT regulatory 
networks [46,48–50]. Mathematical modeling approaches have been further used to characterize 
phenotypic stability factors (PSFs) that can promote and stabilize hybrid E/M states. These PSFs 
include the transcription factors OVOL, GRHL2, NRF2, DNP63a, NUMB and miR-145/OCT4 
[50–54]. These PSFs can function in two related manners. First, coupling these PSFs with the 
decision-making circuit of EMT - miR-200/ZEB expands the parameter space and thereby the 
expected physiological conditions under which a hybrid E/M state can be attained [51–53].  In 
particular, PSF coupling can create a region of parameter space in which the only stable state is a 
hybrid one. Second, these PSFs increase the mean residence time of the hybrid E/M state, and thus 
its expected percentage in a cell population [50]. Experimental validation for these PSFs comes 
from observations that knocking them down destabilizes hybrid E/M phenotype and collective cell 
migration, instead promoting a complete EMT and individual cell migration. Other mechanisms 
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through which a stable hybrid E/M phenotype can be acquired rely on combinatorial treatments 
with EMT-inducing and MET-inducing signals [54,55] or an increase of gene expression noise 
[56].  
 
In summary, these mathematical modeling studies provide insights into the multi-stable nature of 
EMT, particularly the existence and characterization of hybrid E/M states. As we will now see, 
these modeling-predicted hybrid E/M states have been recently characterized experimentally both 
in vitro and in vivo. 
 
In vitro characterization of hybrid E/M phenotypes 
To map the EMT spectrum in ovarian carcinoma, Huang et al. analyzed the protein levels of 
epithelial markers – E-cadherin (E-Cad) and pan-cytokeratin (Pan-CK) and the mesenchymal 
marker – vimentin (Vim) of 42 ovarian carcinoma cell lines. Among these 42 cell lines, 9 epithelial 
cell lines are characterized by E-Cad+/Pan-CK+/Vim-, 7 mesenchymal cell lines are characterized 
by E-Cad-/Pan-CK-/Vim+, and 26 hybrid E/M cell lines are characterized by either E-Cad+/Pan-
CK+/Vim+ (n=18, referred to as intermediate E) or E-Cad-/Pan-CK+/Vim- (n=8, referred to as 
intermediate M) [57]. The intermediate E ovarian carcinoma cell lines exhibit significantly higher 
levels of SNAI1 mRNA and lower levels of ZEB1/2 mRNAs relative to the intermediate M ovarian 
carcinoma cell lines. The different expression patterns of SNAI1 and ZEB1/2 in intermediate E 
and intermediate M is reminiscent of the different characterizations of the hybrid E/M states by Lu 
et al. [42] and Zhang et al. [43]. Interestingly, the intermediate M ovarian carcinoma cell line 
SKOV3 exhibited significantly higher spheroidogenic efficiency, migratory and invasive potential 
relative to the ovarian carcinoma cell lines with other phenotypes. Further studies have revealed 
underlying feedback loops that can regulate such phenotypic plasticity in ovarian cancer [58]. 
 
Similarly, to characterize the EMT spectrum in lung adenocarcinoma, Schliekelman et al. analyzed 
the cell morphologies and the ratios of surface localized E-cadherin to vimentin of 38 non-small 
cell lung cancer (NSCLC) cell lines out of which 9 were binned as epithelial, 9 as mesenchymal 
and 20 as hybrid E/M [59]. Notably, in these experiments the hybrid E/M cell lines are identified 
at a population level and therefore can contain purely individually hybrid E/M cells, or 
alternatively contain a mixture of epithelial and mesenchymal cells or both. Among these hybrid 
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E/M NSCLC cell lines, almost all individual H1975 cells were shown to stably co-express E-
cadherin and vimentin at least for two months over multiple passages, thus representing stable 
hybrid E/M cells [51]. In contrast, individual NSCLC H1944 or H2291 cells express either only 
E-cadherin or only vimentin, thus these cell lines are largely a mixture of epithelial and 
mesenchymal cells [60,61]. When knocking down the predicted PSFs - GRHL2, OVOL2, NUMB 
or NRF2 - via siRNAs in H1975 cells, these hybrid E/M cells transition to a complete 
mesenchymal phenotype [51,53,62]. Another cell line that exhibits hybrid E/M phenotype 
characterized by co-expression of E-cadherin and ZEB1 at a single-cell level is human bladder 
cancer (HBC) RT4. Overexpression of the PSF NRF2 in RT4 cells increases the protein levels of 
both E-cadherin and ZEB1, supporting the predicted role of NRF2 in stabilizing a hybrid E/M 
phenotype. 
 
In addition to cell lines containing either individual hybrid E/M cells or a mixture of E and M cells, 
there are cell lines that exhibit co-existence of hybrid E/M cells together with epithelial and/or 
mesenchymal cells. For example, the NSCLC HCC827 cells contain mostly epithelial cells and a 
subpopulation of individual hybrid E/M cells characterized by co-expression of epithelial markers 
including E-cadherin and miR-200a/b/c and mesenchymal markers including vimentin, ZEB1 and 
SNAI1 [63]. Treatment of the HCC827 cells with the epidermal growth factor receptor (EGFR) 
inhibitor erlotinib induces a stably erlotinib-resistant cell population among which the percentage 
of hybrid E/M cells is increased relative to their parental erlotinib-sensitive HCC827 cells [63], 
indicating a correlation of hybrid E/M phenotypes with therapy resistance. As expected, these 
HCC827-derived erlotinib-resistant cells exhibit collective migration and form more spheroids 
relative to their parental erlotinib-sensitive HCC827 cells [63]. Other NSCLC cell lines such as 
H920 and H2228 have been shown to be mixtures of hybrid E/M and epithelial cells with the 
hybrid E/M ones being dominant [60]. Aside from NSCLC cells, Grosse-Wilde et al. used flow 
cytometry analysis to isolate a subpopulation of breast cancer HMLER cells that are characterized 
by CD24+/CD44+. Most of these CD24+/CD44+ HMLER cells co-express epithelial genes such as 
CDH1 and EPCAM and mesenchymal genes such as VIM and ZEB2 and thus exist in a hybrid 
E/M phenotype [64]. These hybrid E/M HMLER cells demonstrate maximum mammosphere-
forming ability relative to their epithelial and mesenchymal counterparts, highlighting that a hybrid 
E/M phenotype will often be more aggressive than a complete EMT phenotype, a theme which has 
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also found emerging clinical support [65]. Later on, we will discuss how these additional properties 
of hybrid cells may arise due a coupling of the EMT pathway and the network determining 
“stemness”. 
 
As already noted, hybrid E/M phenotypes can be acquired and maintained by combinatorial 
treatments of EMT- and MET-inducing signals. For example, Gould et al. showed that the 
epithelial colon carcinoma DLD1 cells can undergoing a partial EMT and acquire a hybrid E/M 
phenotype co-expressing E-cadherin and vimentin. Such hybrid E/M DLD1 cells are driven by 
simultaneous expression of the TFs - pSP1 and NFATc in response to the combined treatment of 
VEGF-A and TGF-β1/2 [54]. Similarly, Biddle et al. showed that treatment of the oral squamous 
cell carcinoma (OSCC) CA1 and LM cells with TGF-β and retinoic acid simultaneously can 
stabilize a hybrid E/M subpopulation characterized by CD44high/EpCAMlow/−/CD24+ [55]. 
Additional experimental studies characterizing hybrid E/M phenotypes and their implications have 
been reviewed elsewhere [66,67]. In summary, hybrid E/M phenotypes have been observed in 
vitro at a single-cell level across multiple cancer types. 
 
The co-existence of epithelial, mesenchymal and hybrid E/M subpopulations in a single cell line 
indicates a population heterogeneity of EMT. Such heterogeneity can be generated and maintained 
via multiple mechanisms all of which can contribute to the acquisition and maintenance of hybrid 
E/M phenotypes (Figure 2). First, the EMT regulatory networks can be multi-stable [42,43,46,48]. 
Noise in the expression levels of the involved RNAs and proteins can thus cause transitions from 
one stable steady state to another [68]. Such noise may arise from the inherent stochasticity of the 
transcription process in cells [69] or from the random partitioning of parent cell RNAs and proteins 
among the daughter cells at the time of cell division [70–72]. Since both noise sources are cell-
autonomous,, individual epithelial cells may spontaneously undergo a phenotypic transition and 
acquire (or give rise to, in the second scenario) a hybrid E/M phenotype [73]. Thus, one must be 
careful when choosing a cell line for experiments - a cell line known to be epithelial may include 
substantial fractions of hybrid E/M and/or mesenchymal cells [55,73]. Second, the population 
heterogeneity of EMT can arise via cell-cell communication. An example of such a communication 
channel is Notch-Delta-Jagged signaling. Some cells with high levels of Delta/Jagged expression 
act as senders, while other cells with high levels of Notch receptor expression act as receivers. 
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This leads to a population that is inherently heterogeneous - a mix of sender and receiver cells. 
Notch-Delta-Jagged signaling-mediated heterogeneity is closely tied to the emergence of hybrid 
E/M phenotypes [74]. This will be discussed in more detail below. Third, population heterogeneity 
of EMT can arise due to different kinetic parameters controlling gene regulation in different cells. 
Due to the multitude of peripheral factors involved in governing the behavior of a core regulatory 
circuit, the kinetics of the core circuit can vary from cell to cell leading to different responses to 
the same external cues in different cells [46]. This might be connected to the aforementioned 
random partitioning but might arise as well due to different long-lived fluctuations, perhaps related 
to chromatic structure heterogeneity. 
 
 
Figure 2. Multiple mechanisms can lead to a population heterogeneity of EMT. (A) The 
kinetics of gene regulation can vary in different cells due to stochasticity in kinetic parameters. 
Thus, each parameter can exhibit some variation in its value in a given isogenic population (left: 
each curve denotes the distribution of values of an individual parameter in a given population).  
This heterogeneity can lead to cells in the population acquiring different phenotypes in response 
to the same external cues (right: heatmap indicates the emergence of various phenotypes. Each 
row represents a cell and each column represents expression of one gene. Red color represents 
relatively high gene expression and blue color represents relatively low gene expression). (B) Cell-
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cell communication (left) mediated by, for example Notch-Delta-Jagged signaling, can lead to 
cells spontaneously acquiring “signal sender”, “signal receiver” and “signal sender/receiver” 
phenotypes in a population (right, different colors correspond to different cell phenotypes). (C) 
During cell division, noise can lead to asymmetric partitioning of molecules among daughter cells, 
thus leading to various phenotypes of daughter cells. As a result, the fractions of cells exhibiting 
different phenotypes can change over time. 
 
In vivo characterization of hybrid E/M phenotypes 
To identify whether cancer cells can acquire hybrid E/M phenotypes in vivo, Pastushenko et al. 
used fluorescence-activated cell sorting (FACS) to screen cell surface markers of skin squamous 
cell carcinoma (SCC) cells that can undergo spontaneous EMT and generate EpCAM+ epithelial 
cells and EpCAM- mesenchymal-like cells in genetically engineered mouse models [10]. While 
the EpCAM+ cells exhibit homogeneous expression of most of the markers, the EpCAM- cells 
exhibit heterogeneous expression of 17 cell surface markers among which the most 
heterogeneously expressed are CD61, CD51 and CD106. Consequently, the authors used 
combinatorial multicolor FACS analysis of these three markers to further classify the EpCAM- 
cells into 6 subpopulations among which the CD51−CD61−CD106−, CD51+ and CD106+ 
subpopulations exhibit co-expression of the epithelial marker keratin 14 (K14) and the 
mesenchymal marker vimentin, thus can be tentatively considered to be hybrid E/M phenotypes. 
The CD51+CD61+CD106+ and CD51+CD61+ subpopulations, on the other hand, are vimentin 
positive and K14 negative and thus being mesenchymal-like. Intriguingly, the hybrid E/M 
CD51−CD61−CD106− and CD106+ subpopulations generate significantly more metastases relative 
to other subpopulations, though all subpopulations here share similar tumour-propagating 
capacity. Similar results have also been observed in MMTV-PyMT mammary luminal tumours 
[10]. Another study performed by Aiello et al. used a lineage-tracing mouse model of PDAC 
showed that the PDAC cells undergoing EMT can acquire a hybrid E/M phenotype via re-
localization of epithelial proteins such as E-cadherin and claudin-7 from membrane to intracellular 
foci [75]. The emergence of these hybrid E/M PDAC cells indicates that besides transcriptional 
control, post-transcriptional regulation of localization can be also important to mediate the 
existence of hybrid E/M phenotypes. Finally, another study by Puram et al. showed that the head 
and neck squamous cell carcinoma (HNSCC) cells from patients exhibit a hybrid E/M phenotype 
characterized by co-expression of epithelial markers such as EPCAM and KRT17 and 
mesenchymal markers such as vimentin and TGF-β-induced (TGFBI) through single-cell 
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transcriptomic analysis [76]. Intriguingly, these hybrid E/M HNSCC cells tend to localize at the 
leading edge of tumors close to surrounding stroma cells. 
 
In summary, mathematical modeling together with both in vitro and in vivo experimental studies 
consistently demonstrate the existence of multiple hybrid E/M phenotypes characterized by 
varying extents of epithelial and mesenchymal features (Figure 3). It is worth noting that in 
addition to the characterization of the hybrid E/M phenotypes, mathematical modeling of EMT 
regulatory networks have generated many other interesting predictions that have been recently 
validated by experimental studies. First, modeling the core EMT regulatory network – miR-
200/ZEB/miR-34/SNAIL suggests a sequential response of the EMT-TFs SNAIL and ZEB to the 
EMT inducing signal TGF-β [43,44]. When treated with different levels of TGF-β, SNAIL is 
predicted to precede ZEB and to be upregulated at relatively low TGF-β levels. The predicted 
different responses of SNAIL and ZEB has been verified in MCF10A cells [43]. Second, another 
prediction from modeling studies [42,43] is that EMT and MET are not necessarily symmetric 
processes and hysteresis is expected during EMT. The predicted hysteretic behavior of EMT has 
been recently demonstrated during TGF-β induced EMT of NMuMG and EpRAS cells, where the 
levels of E-cadherin exhibit a bimodal transition. Such hysteretic behavior of E-cadherin is 
regulated by the miR-200/ZEB1 circuit and blocking the inhibition of miR-200 by ZEB1 (referred 
to in this study as mutant cells) results in only a unimodal transition of E-cadherin, though these 
mutant cells can still undergo EMT with changes of EMT markers at a similar degree relative to 
the wild type [77]. Moreover, TGF-β induced EMT of mutant cells exhibits significantly decreased 
sphere-formation ability in vitro, decreased frequency of tumor-initiating cells and lung metastases 
in vivo relative to their wild types. These results also confirm a prominent role of the miR-200/ZEB 
circuit in regulating the aspects of EMT dynamics that result in a variety of functional 
consequences. 
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Figure 3. Emergence of hybrid E/M phenotypes demonstrated by a combination of 
theoretical and experimental efforts. The cell lines NSCLC H1975 and HBC RT4 exhibit a 
hybrid E/M phenotype at a single-cell level. Hybrid E/M phenotypes have also been characterized 
in vivo using mouse models of SCC and PDAC. 
 
EMT regulation by cell cooperation 
Notch signaling 
Although EMT is fundamentally an individual cell phenomenon, it can also be regulated by cell 
cooperation such as Notch signaling. Notch signaling is a cell-cell communication mechanism and 
highly conserved across species. Originally characterized in Drosophila development, Notch 
signaling is a conserved and well-known regulator of multiple hallmarks of cancer, including 
angiogenesis and EMT [78–80].  
 
The Notch signaling cascade is initiated by the binding of the Notch transmembrane receptor with 
a ligand belonging to a neighboring cell. This binding leads to the cleavage of the Notch 
intracellular domain (NICD), which is then released in the cytoplasm and transported to the cell 
nucleus, where it acts as a transcriptional cofactor [81]. Notch signaling is deeply coupled to the 
EMT regulatory networks discussed in previous sections. For example, on one hand, EMT-
inhibiting miRNAs miR-34 and miR-200 reduce the levels of Notch receptor and ligands [82–84] 
by translational regulation [85]. On the other hand, NICD promotes the transcription of SNAIL 
and thus acts as an EMT inducer [86,87]. Therefore, cancer cells undergoing EMT can in turn 
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induce EMT in their neighboring cells through the binding of their ligands to a neighbor’s Notch 
receptors.     
 
As often seen in the developmental context, Notch signaling can give rise to different spatial 
patterns of cell phenotypes due to feedback regulation between NICD and various alternate 
ligands. Specifically, NICD transcriptionally represses ligands of the Delta family but activates 
ligands of the Jagged family. Therefore, signaling through the Notch-Delta pathway typically 
promotes opposite cell fates in neighboring cells, or ‘lateral inhibition’. This is accomplished by 
amplifying initial differences in the levels of receptors and ligands, ultimately leading to one cell 
with high levels of Notch receptor and low levels of Delta ligand (receiver cell) and a neighbor 
cell with low Notch and high Delta (sender cell) [88,89]. Conversely, Notch-Jagged signaling 
typically promotes a similar cell fate in neighboring cells, or ‘lateral induction’, because NICD 
upregulates Jagged ligands [90]. 
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Figure 4. Notch-Delta and Notch-Jagged signaling give rise to opposite cell patterning of 
EMT. (A) Coupling of Notch-Delta signaling with the core EMT regulatory circuit. NICD 
suppresses the endogenous expression of Delta ligands upon activation of Notch receptors by 
exogenous Delta ligands (left, red color represents the ‘receiver phenotype’ (high notch), green 
color represents ‘sender phenotype’ (high delta)). Cell patterning of EMT in presence of a strong 
Notch-Delta signaling (right). (B) Coupling of Notch-Jagged signaling with the core EMT 
regulatory circuit. NICD promotes the endogenous expression of Jagged ligands upon activation 
of Notch receptors by exogenous Jagged ligands (left, blue color represents a ‘sender/receiver 
phenotype’ (high Jagged)). Cell patterning of EMT in presence of a strong Notch-Jagged signaling 
(right). Hexagons with different colors depict epithelial (green), hybrid E/M (yellow) and 
mesenchymal (red) cells. Figures in the right panel are adapted from [53]. 
 
The cell patterning mediated by Notch ligands can modulate epithelial-mesenchymal plasticity in 
a tumor tissue due to the aforementioned coupling between Notch and the EMT regulatory circuits. 
Intracellular Notch signaling activated by either Delta or Jagged can activate EMT. However, 
mathematical modeling of the coupled regulatory networks regulating EMT and Notch signaling 
suggests that Notch-Delta and Notch-Jagged signaling have dramatically different outcomes at a 
multi-cellular level. While Notch-Delta signaling promotes a spatial arrangement where cells in a 
partial or complete EMT are surrounded by epithelial cells, Notch-Jagged signaling can give rise 
to clusters of hybrid epithelial/mesenchymal (E/M) cells [74] (Figure 4). Indeed, Jagged1 is one 
of the top differentially expressed genes in collectively migrating cells of breast cancer [12,91]. 
These observations suggest that Jagged1 can act as an intercellular PSF that stabilizes a hybrid 
E/M phenotype in a non-cell autonomous manner. Therefore, in addition to ‘conventional’ PSF 
proteins that promote a partial EMT through direct crosstalk with the EMT regulatory circuitry, 
such as OVOL, GRHL2, and NRF2 [51,52,62], other PSFs can facilitate a partial EMT and the 
formation of CTC clusters by activating Notch-Jagged signaling and/or inhibiting Notch-Delta 
signaling. For example, NUMB/NUMBL that forms a negative feedback loop with Notch [92–94] 
can prevent a complete EMT, and consistent with that identification, knockdown of NUMB/ 
NUMBL result in a mesenchymal phenotype and enables individual migration of the hybrid E/M 
NSCLC H1975 cells that typically migrate collectively [53]. 
 
Interaction among epithelial, hybrid E/M, and mesenchymal cells 
Similar to bidirectional interactions among epithelium and mesenchyme during organ 
development [95], there may be crosstalk and cooperation among cells exhibiting varying extents 
of EMT, which can accelerate tumor aggressiveness [96–98]. Hybrid E/M cells can facilitate such 
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crosstalk, due to their plasticity that can generate and maintain epithelial-mesenchymal 
heterogeneity at a population level; such plasticity is limited for cells on either end of the EMT 
spectrum. Moreover, hybrid E/M cells can maintain cell-cell adhesion via E-cadherin, and thus 
potentially enabling formation of heterotypic clusters of CTCs with cells of varying EMT statuses 
[99]. Last but not least, a recent study highlighted that the hybrid E/M HMLER cells, but not a 
mixture of nonplastic ‘extremely epithelial’ (xE) cells and nonplastic ‘extremely mesenchymal’ 
(xM) cells, account for high tumorigenicity in vivo [100]. Notably, the nonplastic xE cells are 
created by ZEB1 knockdown and the nonplastic xM cells are created by constitutive ZEB1 
expression, which supports the role of ZEB1 in mediating EMT [42,44]. 
  
Whether a mixture of E and M cells is sufficient to initiate the metastatic cascade and successfully 
form metastases remains to be resolved. Few molecular mechanisms enabling crosstalk between 
E and M cells have been elucidated recently. Tsuji et al. demonstrated that when EMT and non-
EMT cells are inoculated subcutaneously in mice, they both establish primary tumors, but neither 
of them form lung metastases [96]; the ability to invade local tissues and enter circulation is 
demonstrated only by EMT cells. Further, when both cell types are injected intravenously, non-
EMT cells form overt metastases, but the metastatic ability of EMT cells is compromised. Finally, 
when a mixture of EMT and non-EMT cells is subcutaneously injected, both cell types can 
intravasate but only non-EMT cells form lung metastases. Put together, these observations indicate 
a possible cooperation between EMT and non-EMT cells – while EMT cells can cleave the matrix 
to make way for both cell populations to intravasate, the non-EMT cells can colonize distant organs. 
This study did not identify any juxtacrine and/or paracrine signaling underlying this cooperation, 
but recent in vitro co-culture experiments of EMT and non-EMT cells have identified a few players 
that can mediate this crosstalk. HMLER cells overexpressing TWIST or SNAIL have been shown 
to impart migratory and invasive traits in vitro to control HMLER cells via paracrine Hedgehog 
signaling, but without explicitly inducing any morphological or molecular changes associated 
typically with EMT [97]. The authors also demonstrated that the EMT cells are able to increase 
the metastatic propensity of non-EMT cells in vivo, thus lending further credence to the notion that 
EMT cells can stimulate the migration of non-EMT cells. This idea is further strengthened by 
another in vitro analysis of sublines derived from prostate cancer PC-3 cells, where the relatively 
more epithelial PC-3/Mc cells, when co-cultured with post-EMT PC-3/S cells, have increased 
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invasive potential which persisted for around 7 days after the co-culture but eventually decline 
after being segregated from PC-3/S cells [101]. This increased invasive response is also observed 
upon co-culture of PC-3/Mc cells with NIH3T3 fibroblasts, suggesting that the invasiveness of 
non-EMT cells can be increased by both tumor and non-tumor mesenchymal cells [101]. In vivo 
experiments for individual or co-injection of PC-3/S and/or PC-3/Mc cells corroborate previous 
observations that the post-EMT cells had little, if any, contribution to distant organ colonization 
[101]. Put together, these findings are reminiscent of in vivo studies showing that a persistent EMT 
activation can reduce metastases formation [6,102], and clinical evidence that carcinoma 
metastases are largely epithelial [103].  
 
Reversible transitions among epithelial and mesenchymal phenotypes of disseminating cells has 
been dogmatically considered as the driving engine of metastasis for a long time [1,104,105] (also 
referred to as the ‘sequential metastasis’ model) [98], but with the proposed key role of EMT and 
MET being relooked at more carefully [20], the possibility of a cooperative journey taken together 
by epithelial and mesenchymal cells where they necessarily do not change their phenotypes cannot 
be ruled out (also referred to as the ‘cooperative metastasis model’) [98]. Multiple possibilities 
may underlie this cooperation: a) epithelial cells facilitate MET of mesenchymal cells, b) 
mesenchymal cells facilitate the survival, persistence and re-adhesion of epithelial cells during 
colonization, c) epithelial and mesenchymal cells exchange survival signals, d) a combination of 
the above. Nevertheless, collective transport of epithelial and mesenchymal cells is likely to be 
more effective for colonization as compared to that of one population alone. However, the role of 
hybrid E/M cells in this cooperative metastasis model remains to be explored.   
 
What mechanisms may allow such collective migration of epithelial and mesenchymal cells? In 
developmental contexts, epithelial or mesenchymal cells have been seen to migrate collectively 
through respective cell-cell contacts mediated by E-cadherin or N-cadherin [106,107]. Recently, a 
N-cadherin/E-cadherin mechanically active heterophilic adhesion among the cancer-associated 
fibroblasts and cancer cells was reported to guide collective migration of tumor cells [108]. Given 
that the heterophilic E-cadherin/N-cadherin interaction has been proposed to be of similar affinity 
as that of homophilic E-cadherin interactions [109], collective cell migration can be expected to 
be observed among cells with varying levels of E-cadherin and N-cadherin. Another study reports 
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a short-ranged interaction via EGF/CSF-1 paracrine axis to mediate macrophage-driven tumor cell 
migration [110,111]. CSF-1/CSF-1R axis has been recently proposed to associate with a hybrid 
E/M phenotype in inflammatory breast cancer [108] - a highly aggressive breast cancer subtype 
that metastasizes via clusters or emboli of circulating tumor cells [91]. These mechanisms may 
mediate, at least in part, a collective cooperative migration of cells in varying hues of EMT. 
Increased plasticity of hybrid E/M cells may be necessary and sufficient to maintain and propagate 
the non-genetic heterogeneity in terms of EMT status in a given isogenic cancer cell population. 
 
Mechanical control of EMT by ECM 
In addition to chemical communication, the stiffness of ECM also plays a key role in regulating 
EMT. For example, cancer cells when cultured in stiffer substrates exhibit increased migratory and 
invasive ability and become more mesenchymal-like [112]. Alternation in ECM stiffness can 
trigger multiple signaling pathways to regulate EMT, such as TWIST1-G3BP2 [23], HA-CD44 
[113] , MRTF-A [114], PI3K/Akt [115] and YAP/TAZ [116]. Yet, the reversibility of ECM 
stiffness-induced EMT can be cell line-dependent. For example, the mammary epithelial cells that 
have undergone EMT in a stiff substrate partially revert to epithelial phenotype [117], while the 
colon carcinoma HCT-8 cells can retain their mesenchymal-like phenotype, all after being re-
cultured in the compliant substrate [118]. It is worth noting that cells undergoing EMT can in turn 
regulate ECM. For example, the LOX-family enzymes are upregulated in fibrosis and upregulation 
of LOX-family enzymes can directly increase connectivity of collagen fibers, stabilize and stiffen 
the collagen networks [119,120]. Given the importance of mechanical regulation of EMT, 
mathematical models that integrate mechanical with chemical signaling networks need to be 
developed to better understand EMT-ECM dynamics [121]. 
 
Quantification of the EMT spectrum 
Our discussion so far has hopefully made it clear that cells undergoing EMT can acquire a spectrum 
of hybrid E/M states both in vitro and in vivo. However, the lack of a rigorous quantification of 
the EMT spectrum, namely, the exact proportions of epithelial, mesenchymal and hybrid E/M 
subpopulations of cell lines and clinical samples, can lead to potentially contradictory conclusions 
regarding the necessity and functional roles of EMT and MET in metastasis [15–17,102,122,123].  
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Cells undergoing EMT typically alter both their omics profiles and morphologies. Therefore, in 
principle, the EMT spectrum can be quantified via evaluating the change of cell morphology and/or 
their omics profiles. To classify epithelial and mesenchymal phenotype at a single-cell level, 
Leggett et al. developed a probabilistic classification scheme using Gaussian mixture model 
(GMM) focusing on 4 morphological features of single cells – maximum radius of the nucleus, 
vimentin area, cytoplasm form factor and maximum feret diameter of cytoplasm [124]. The GMM 
is trained using the morphological features of DMSO-treated (epithelial) and 4-hydroxytamoxifen 
(OHT)-treated (mesenchymal) human mammary MCF-10A cells which are transfected with an 
inducible Snail construct, referred to as MCF-10A Snail cells. The probabilistic GMM model has 
revealed various EMT kinetics of MCF-10A Snail cells when induced by TGF-β1, plating density 
and the microtubule inhibitor Taxol respectively. This GMM model also provides insight into the 
EMT status of individual cells which may be overlooked by population-average analysis. 
However, this method only focuses on a binary classification of EMT – epithelial or mesenchymal 
and one missing piece of this model is the classification of hybrid E/M phenotypes.  
 
To quantitatively measure the EMT status of cell lines with specific attention to a hybrid E/M 
phenotype, George et al. developed an EMT scoring metric to calculate the probability of a given 
sample to be hybrid E/M phenotype and assign a score between 0 and 2 with 0 being fully 
epithelial, 2 being fully mesenchymal and 1 representing hybrid E/M [125]. Using the gene 
expression data of NCI-60 human tumor cell lines as the training set, the ratio of VIM to CDH1 
together with CLDN7 expression are identified as the best-fit pair of predictors to classify EMT 
phenotypes. This EMT scoring metric has been used to characterize multiple hybrid E/M cancer 
cell lines including A549 and DU145. Furthermore, this EMT scoring metric has been extended 
to distinguish hybrid E/M cells from mixtures of epithelial and mesenchymal cells [60]. Another 
EMT scoring metric developed by Tan et al. assigns a score between -1 and 1 to a given sample 
with -1 being fully epithelial and 1 being fully mesenchymal [126]. Both George et al. and Tan et 
al. demonstrated that patient samples that are more mesenchymal-like do not necessarily correlate 
with worse overall and disease-free survival results and do not always show resistance to 
chemotherapy, indicating a subtype-dependent role of EMT in cancer progression and therapy 
resistance. In summary, these methods to quantify EMT status help address the multifaced roles 
of EMT in tumor progression and patient prognosis. 
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EMT and CTC clusters 
Cancer cells that acquire a hybrid E/M phenotype maintain both epithelial (e.g. cell-cell adhesion) 
and mesenchymal (e.g. migration) features thus can migrate collectively as a cluster. Such clusters 
of migrating tumor cells have been shown to be one of the primary instigators of metastases 
[12,127]. The experimental studies supporting this notion are discussed below. 
 
Using multicolor lineage tracing, Cheung et al. showed by two sets of experiments that the CTC 
clusters are mainly formed by multi-cellular clusters from the primary tumors. In the first set of 
experiments, two differently colored populations - mTomato+ and CFP+ MMTV-PyMT tumor 
organoids were respectively transplanted into the right and left flanks of a nonfluorescent mouse. 
After 6 to 8 weeks, only single-colored metastases were observed in lung. In the second set of 
experiments, mTomato+ single cells isolated by FACS were transplanted into a nonfluorescent 
mouse via tail-vein injection and 2 days later FACS isolated CFP+ single cells were injected into 
the same mouse. After 2 days, exclusively single-colored metastases were observed in lung. These 
two sets of experiments suggest that the polyclonal metastases in lung is more effectively 
generated by multicellular seeds and not by serial aggregation of single tumor cells [12]. The CTC 
clusters exhibit enriched expression of an epithelial cytoskeletal protein K14 that is required for 
the collective invasive behavior and distant metastasis. Another study supporting the idea that CTC 
clusters can arise as oligoclonal groups of cells detached from the primary tumors is Aceto et al. 
who identified plakoglobin as a key mediator for CTC cluster formation [128].   
 
An alternative mechanism – that CTC clusters can be formed via aggregation of single CTCs in 
circulation - has been recently demonstrated by Liu et al. using intravital multiphoton microscopic 
imaging in both patient-derived xenograft (PDX) models of triple negative breast cancer (TNBC) 
and PyMT transgenic mouse models [127]. Liu et al. first showed that in chemoattractant-
containing matrigel about 20% of invasion events of the tumor cells collected from the PDX 
models occur as multicellular aggregates, and in suspension culture individual CTCs derived from 
a breast cancer patient aggregate into clusters within 1 to 2 hours. These results indicate that single 
CTCs can aggregate in vitro. The authors further co-infused eGFP+ and tdTomato+ single MDA-
MB-231 cells via the tail vein and observed that about 92% of lung metastasis are dual-color 
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aggregates within 2 hours. The percentage of the dual-colored aggregates is affected by the timing 
of the eGFP+ and tdTomato+ entering blood vessels. Consequently, sequential infusion of the 
tdTomato+ cells 5 minutes, 10 minutes and 2 hours after the infusion of the eGFP+ cells result in 
gradually decreased percentages (27%, 16% and 10%) of the dual-colored aggregates. The authors 
further showed that the CTC clusters exhibit notably enriched expression of CD44, and that the 
intercellular CD44 homophilic interaction is responsible for the aggregation of single CTCs. 
 
One major difference in the studies by Cheung et al.  and Liu et al. is the timing of the second-
colored single cells entering the blood vessels. Cheung et al. injected the second-colored cells into 
the tail vein 2 days after the injection of the first-colored cells while Liu et al. waited for at most 
2 hours to inject the second-colored cells. As discussed by Liu et al., the timing of the second-
colored cells entering the blood vessel could have significant effect on the percentages of dual-
colored lung metastases. From our perspective, the key issue in these two studies seems to be the 
lifetime and density of the injected single cancer cells. Since it is not clear how often the injected 
cells are expected to reach the bloodstream, it is hard to evaluate which protocol is a better match 
to reality. The experiments by Cheung et al. where two differently colored populations of tumor 
organoids are injected respectively into the right and left flanks of nonfluorescent mice seems to 
be a better approach since the interaction of cells in the bloodstream is determined naturally rather 
than by the experimenters. Nonetheless, both studies showed that the CTC clusters significantly 
promote colony formation and lung polyclonal metastases in vivo. Liu et al. showed through 
CellSearch platform-based blood analysis that the breast cancer patients with CTC clusters exhibit 
significantly worse overall survival results relative to those with only single CTCs. And, CTC 
clusters in different contexts can be different. For example, Khalil et al. showed that though 
invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC) exhibit collective invasion 
patterns, the collective invasion in IDC lesions maintains intercellular E-cadherin while collective 
invasion in ILC lesions loses intercellular E-cadherin but retains CD44 for intercellular junctions 
[129]. All together, these studies suggest that CTC clusters can in principle be generated both by 
cohesive shedding from the primary tumors and/or serial aggregation of single cells in the 
circulation.  
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To model the migration of CTC clusters, Bocci et al. proposed a simple biophysical model where 
cancer cells can undergo a partial EMT that allows both single-cell and clustered-cell migration, 
or a complete EMT that only allows single-cell migration [130]. According to this reduced physical 
model, a tumor can undergo a transition from primarily single cell-based invasion to collective 
invasion. Strikingly, this theoretical framework reproduces multiple CTC cluster size distributions 
measured in patients and mouse models across cancer types, hence suggesting the existence of a 
unifying set of principles governing cancer cell migration [130]. 
 
Adding to the complexity of the problem, CTC clusters can associate with non-cancer cells 
including platelets and/or immune cells such as tumor-associated macrophages and neutrophils 
[131–133]. In particular, it is well recognized that interactions between macrophages and tumor 
cells are very important for tumor cell intravasation and extravasation, though the detailed 
mechanisms have not been elucidated [134,135]. In addition, the CTC-neutrophil clusters lead to 
more efficient metastasis relative to CTCs alone [131]. Future studies need to be performed to 
elucidate the cross-talk between CTC clusters and different types of immune cells.  
 
EMT and stemness in tumor microenvironment 
We have already come across the fact that besides the migratory and invasive traits conferred by 
EMT, some cancer cells undergoing EMT can also acquire an enhanced ability to drive tumor 
initiation and an enhanced therapy resistance. These properties are associated with the notion of 
‘stemness’, and such cells are sometimes referred to as cancer stem cells (CSCs). The connection 
between EMT and stemness was first proposed by Brabletz et al. [24] more than a decade ago 
based on the premise that EMT and stemness cannot explain the different steps of the metastatic 
cascade when considered as separate and independent processes [24]. Indeed, increasing 
experimental evidence suggests a strong association of EMT with stemness. For instance, human 
mammary epithelial cells (HMLEs) undergoing EMT can express stem cell markers and exhibit 
increased mammosphere formation [122]. Moreover, reversing EMT via knockdown of SNAIL 
represses stemness and tumor growth in ovarian cancer [136]. This and other evidence suggests 
that the activation of the EMT program leads to the acquisition of stemness [137]. This correlation, 
however, is not absolute, and several other experimental papers have claimed that stemness can 
occasionally correlate with an epithelial phenotype or suppression of EMT [101,102,138].  
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Revisiting the EMT-CSC connection through the lenses of epithelial-mesenchymal plasticity and 
hybrid E/M phenotypes, however, offers a more consistent picture. Mathematical modeling 
approaches have been applied to decode the connection of EMT with stemness via simulating the 
coupled decision-making regulatory networks of EMT and stemness. Specifically, EMT activation 
can downregulate let-7, a miRNA typically associated with repressing stemness. Let-7 can bind to 
ZEB and promote its degradation. These two processes can settle at an intermediate level of let-7 
and ZEB leading to hybrid E/M CSCs [139]. This association, however, can vary depending on 
the coupling between the modules governing EMT and stemness, allowing for CSCs in an 
epithelial, mesenchymal or hybrid E/M phenotype [139]. In addition, local perturbations in the 
tumor microenvironment such as TGF-β or Notch signaling also can modulate the association of 
CSCs with different EMT phenotypes [140,141]. All told, emerging evidence from theoretical and 
experimental studies tends to associate the hybrid epithelial/mesenchymal phenotypes with 
stemness [139,140,142–145].  
 
Along these lines, the association of hybrid E/M phenotypes with stemness can be promoted by 
the PSFs – OVOL and Jagged1. Indeed, Jagged1 is typically overexpressed in CSC populations as 
compared with non-CSCs in multiple types of cancer including glioblastoma, pancreatic cancer, 
colon cancer, and breast cancer [22,146–148]. Through modeling the coupling of the regulatory 
networks governing EMT, stemness and Notch signaling, Bocci et al. proposed that Jagged1 
facilitates a ‘window of opportunity’ that confers maximal invasion potential in terms of EMT and 
stemness [140,145]. A follow-up work showed that knockdown of Jagged1 impairs breast 
organoid formation in vitro, therefore highlighting a causal relationship between Jagged1 and 
stemness [141]. 
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Figure 5. The spatial patterning of CSCs with different EMT phenotypes. Tumor-stroma 
interactions can give rise to a gradient of TGF- β (top, blue scale). In the periphery of the tumor, 
most cells are mesenchymal (red spheres), while the interior is mostly composed by hybrid E/M 
and epithelial cells (yellow and green spheres, respectively). CSCs are mostly mesenchymal in the 
periphery (black-dotted red spheres) and mostly hybrid E/M in the interior (black-dotted yellow 
spheres). 
 
Subpopulations of CSCs with different EMT phenotypes can be representative of the spatial 
organization of a tumor tissue. In breast cancer, CD24-/CD44+ mesenchymal CSCs are typically 
located toward the invasive edge of the tumor by the tumor-stroma interface, while ALDH1+ CSCs 
are found in the more interior region [149]. Interestingly, ALDH1+ CSCs were originally 
considered as epithelial-like, but their RNA sequencing (RNA-Seq) data has later shown that these 
cells lean more toward a hybrid E/M phenotype and share several genes with TNBC signature 
[150]. Recently, Bocci et al. have argued that this spatial segregation can be qualitatively explained 
by the interplay of cancer cells with the tumor microenvironment [141]. Cytokines such as the 
EMT-inducer TGF-β are typically secreted at the tumor-stroma interface and give rise to a gradient 
of EMT-inducing signal throughout the tumor tissue. Therefore, CSCs at the invasive edge are 
highly exposed to TGF-β and tend to undergo a complete EMT leading to a fully mesenchymal 
phenotype, while CSCs in the interior maintain a hybrid E/M phenotype [141] (Figure 5). 
Consistently, in non-small cell lung CSCs, a subpopulation of mesenchymal CSCs exhibits high 
expression of TGF-β targets such as SNAI1 and ZEB1, as compared to a hybrid E/M CSC 
population [140]. 
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In summary, EMT and CSC formation represent two essential axes of tumor progression, whose 
connection is modulated by factors including tumor microenvironment and cell-cell signaling 
[141,149,151,152]. The stem cell paradigm inherited from developmental biology implies a 
hierarchical lineage of cells that gradually but irreversibly differentiate [153,154]. In the context 
of cancer, however, stemness has proven to be a dynamical property that cells can gain and lose 
[155–157]. The complex interplay between EMT, stemness and tumor microenvironment gives 
rise to tumor heterogeneity that still represents the major challenge hindering metastasis and 
therapy resistance [151]. 
 
EMT and immune suppression 
In addition to cancer cells, a solid tumor harbors other types of cells which form the tumor 
microenvironment and strongly affects cancer outcome [26]. Specifically, many groups have 
investigated the roles of immune cells in cancer progression. Certain types of immune cells, such 
as macrophages and T cells, can comprise up to 50% of the cells in a solid tumor [27]. These 
immune cells usually polarize into phenotypes, such as M2-like macrophages and regulatory T 
helper cells (Tregs), that promote tumor progression via suppressing the activity or viability of 
anti-cancerous immune cells, e.g., M1-like macrophages and cancer-killing T effector cells 
[26,27,158]. Our goal here is to focus on the role of EMT in this tumor-immune interplay. 
 
A series of mathematical models have been proposed to understand the roles of tumor-immune 
interactions in polarizing the cytokine-immune cell network into states dominated by either 
immune-promoting or immune-suppressing populations [159–164]. Such modeling frameworks 
can help to design effective perturbations to revert the immune microenvironment from an 
immune-suppressing to an immune-promoting one. Many of these models consider the fact that 
macrophages and cancer cells can directly interact with each other and regulate the behaviors of 
one another, as shown by many in vitro experiments [165–170]. The interactions between 
macrophages and cancer cells are formidably complex, and the emergent dynamics can be non-
intuitive. A series of mathematical models capturing these interactions suggests that cancer cells 
in the epithelial-like state (less aggressive) and M1-like macrophages might form a stable 
ecosystem, whereas cancer cells in the mesenchymal-like state (more aggressive) and M2-like 
macrophages form another stable pair [171].  
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The question of establishing an immune-dominated versus immune-suppressed microenvironment 
should have an effect on the activity of cd8+ effector T-cells. There have been studies suggesting 
that T cells tend to be excluded from tumors enriched by mesenchymal-like cancer cells [172,173]; 
we will discuss this further below. Combining this data with the modeling results, one could argue 
that interactions between macrophages and cancer cells drive the macrophages to be M2-like and 
the cancer cells to be mesenchymal-like; and due to the effects of M2-like macrophages, T cells 
may be excluded from tumor areas enriched with mesenchymal-like cancer cells. Since both the 
infiltration of cancer-killing immune cells [33–39] and the epithelial-mesenchymal plasticity of 
cancer cells are important for the prognosis of cancer patients, it is clearly valuable to evaluate the 
association and ultimately the casual relationship between the two.  
 
In the following, we will first describe in greater detail the corresponding in vitro and in vivo 
experiments as well as analyses of gene expression data from The Cancer Genome Atlas (TCGA) 
(Figure 6). Finally, we discuss the potential causal relationship between the EMT status of cancer 
cells and the infiltration of cancer-killing immune cells. 
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Figure 6. The relationship between EMT and immune response as shown by various 
approaches. 
 
In vitro characterization of the immune-suppressing role of mesenchymal-like cancer cells 
For the interaction between mesenchymal-like cancer cells and immune cells, TGF-β signaling has 
been studied extensively. TGF-β is a well-known EMT inducer [21] and can be secreted by tumor-
associated fibroblasts [174,175] and tumor-associated macrophages [176]. TGF-β signaling can 
impair maturation, differentiation, and/or activation of both innate and adaptive immune cells 
[31,177]. Specifically, TGF-β can inhibit the functions of cytotoxic T-cell functions [178,179]. In 
the co-culture experiments, Joffroy et al. showed that TGF-β secreted by cancer cells induces the 
differentiation of CD4+ T cells into Treg (Foxp3+) cells, which are immune-modulating cells [178]. 
Similar cancer-cell dependent expansion of CD4+Foxp3+ T cells is also shown by Kudo-Saito et 
al. when co-culturing SNAIL-enhanced mouse melanoma B16F10 cells with CD4+ T cells [172]. 
Furthermore, TGF-β can downregulate the MHC class I proteins as shown in prostate cancer [180] 
as well as NSCLC cell lines [181]. 
 
Aside from TGF-β, the PD-L1/PD-1 axis has also attracted attentions due to its implications in the 
immune-checkpoint blockade therapy. Presumably, PD-L1 expressed by cancer cells can bind to 
PD-1 expressed on the surface of cancer-killing immune cells, which will modulate their cytotoxic 
functions. It is shown that when driving EMT via downregulating miR-200 and overexpressing 
ZEB1, PD-L1 expression by cancer cells is upregulated [182]. Therefore, mesenchymal-like 
cancer cells could be more resistant to cancer-killing immune cells by upregulating PD-L1. 
Interestingly, expression levels of both TGF-β1 and PD-L1 by cancer cells can be induced under 
hypoxic conditions [183–185]. The hypoxia-induced EMT can promote immunosuppression via 
induced expression of indoleamine 2, 3-dioxygenase (IDO, another T-cell suppressing factor) in 
monocyte-derived macrophages [186]. 
 
EMT can also be induced when cancer cells are challenged by immune cells or inflammatory 
cytokines [187]. In addition, cancer cells can be equipped with immunomodulatory effects which 
interfere with proliferation, differentiation and apoptosis of NK, T-cell, and B-cell populations 
[187]. As was the case for hypoxia, the IDO pathway is important for the immunomodulatory 
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effects on T cells after inflammation-induced EMT [187]. These experimental results are 
potentially helpful for establishing a potential causal relationship between EMT of cancer cells 
and the infiltration of cytotoxic immune cells. 
 
In vivo characterization of the immune-suppressing role of mesenchymal-like cancer cells 
Generally, in vivo experiments using mouse models show that tumors formed by mesenchymal-
like cancer cells are less infiltrated with cancer-killing immune cells and/or more infiltrated by 
immune-suppressing immune cells. For example, Kudo-Saito et al. showed that in mice, compared 
with tumors formed by mock-transfected B16F10 cells, tumors derived from Snail-transduced 
B16F10 cells exhibit less tumor-infiltrating CD8+ T cells, while more Tregs, and form more lung 
metastases [172]. In the same mouse model, the chemokine CCL2 can recruit immune-modulating 
populations such as MDSC and macrophages [188], which are responsible for creating the 
immune-suppressing microenvironment. In addition, in a mouse model of breast cancer [173], 
tumors formed by mesenchymal carcinoma cell lines contained more Tregs, M2 macrophages and 
exhausted CD8+ T cells, whereas tumors formed by more epithelial carcinoma cell lines contained 
CD8+ T cells and M1 macrophages. Furthermore, using transgenic mouse models, Spranger et al. 
showed that an active β-catenin signaling in cancer cells contributes to a lack of T cell infiltration 
in tumor sites and resistance to anti-PD-L1 and/or anti-CTLA4 mAb therapy [189]. 
 
In summary, from the perspective of direct experiment in vitro or in preclinical models it is 
becoming clear that mesenchymal-like cancer cells can directly suppress the function of cancer-
killing immune cells as well as promote the immune-suppressing microenvironment by recruiting 
or polarizing immune-suppressing immune cells. Following this logic, one would expect a lower 
presence of functional cancer-killing immune cells in the tumor area enriched with mesenchymal-
like cancer cells. 
 
Gene expression data analysis 
What about the results for patients? Unfortunately, the overall picture here as it emerges from 
TCGA data analyses tends to suggest that while mesenchymal tumors are generally enriched with 
immune-suppressing cells, they are often enriched with cancer-killing immune cells as well, as 
compared with epithelial tumors. For example, Mak et al. showed that the pan-cancer tumors 
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samples with high EMT scores correlate with high expression of several immune checkpoints 
including PD-1, PD-L1, CTLA4, OX40L, and PD-L2 [190]. Lou et al. observed similar trend in 
lung cancer patients with early or advanced NSCLC adenocarcinomas [191]. Aside from the 
immune checkpoint markers, Lou et al. also found that the lung tumors that displayed an EMT 
phenotype also have a higher infiltration of Tregs. Interestingly, in their work, some immune 
costimulatory molecules such as CD80 and CD86 as well as IFN-g signals are more highly 
expressed in “mesenchymal” lung adenocarcinoma. Reports also suggest that, in the claudin-low 
subtype of breast and bladder cancer, which are mesenchymal-like, tumors are generally well-
inflamed by immune-promoting immune cells but these cells are under active immunosuppression 
[192]. 
 
It should be noted that data in TCGA is rarely from tumor cells exclusively, thus the mesenchymal 
features seen there may be a consequence of higher infiltration of stromal cells. Conversely, 
analysis of epithelial markers [193] may not be biased by stromal cells. When investigating the 
epithelial marker ESRP1 for melanoma samples in TCGA dataset, Yao et al. found that a high 
infiltrating lymphocyte activity is enriched in ESRP1-low melanoma samples which have 
enhanced mesenchymal features [193]. The lymphocyte activity was evaluated by the gene 
expression of two cytotoxic agents - perforin (PRF1) and granzyme A (GZMA). Considering the 
use of an epithelial marker instead of mesenchymal markers, this work may be a strong piece of 
evidence, since the contamination by mesenchymal markers from non-cancer cells is supposed to 
be low. However, the immune infiltration still needs to be defined rigorously. It is possible that 
cytotoxic immune cells are constrained to lie in the tumor stroma instead of infiltrating into the 
tumor islets, though many of them infiltrate into the core of the tumor. For these tumors, the bulk 
tumor gene expression data will give a high infiltration score of cytotoxic immune cells. If these 
tumors happen to be ESRP1-low tumors, we are likely to conclude that a higher infiltration of 
cytotoxic immune cells is associated with more mesenchymal-like cancer cells. 
 
Although the above-mentioned evidence tends to suggest that a higher infiltration of cytotoxic 
immune cells associates with the mesenchymal features of tumor samples, the jury is still out, and 
an opposite trend has been reported elsewhere. For example, Chae et al. reported that EMT is 
associated with significantly lower infiltration of CD4/CD8 T cells in squamous cell carcinoma 
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[194]. In addition, high numbers of CD8+ TILs have been shown to correlate with low SNAIL 
expression in extrahepatic cholangiocarcinoma [195]. Furthermore, in bladder cancers, patients 
with tumors characterized by an epithelial (luminal) phenotype have a better response rate when 
treated with anti-PD-L1 therapy compared to those harboring basal subtype [196], which are 
mesenchymal-like [197]. Since it has been suggested that patients who respond to anti-PD-L1 
therapy usually have pre-existed CD8+ T cells [198] which can be unleashed by the therapy, it is 
likely that in this particular study, epithelial-like tumors are better infiltrated by CD8+ T cells than 
mesenchymal-like tumors. In addition, in muscle-invasive urothelial bladder cancer (MIUBC), 
activation of β-catenin pathway is found in the most common non-T cell-inflamed MIUBCs [199].  
 
In summary, most of the gene expression analyses point towards a positive correlation between 
mesenchymal-like cancer cells and the higher infiltration of both immune-promoting and immune-
suppressing immune cells, which seems the opposite of the trend revealed by in vitro co-culture 
experiments and in vivo mouse models. The inconsistency can be simply due to the fact that 
different analyses use varying standards of assessing the abundance of cancer-killing immune 
cells, for example, gene expression signatures of cancer-killing immune cells [189] or the 
percentage of cancer-killing immune cells among all (immune) cells [173]. In addition, the selected 
regions of interest (ROI) can also be inconsistent - core vs. margin – with varying immune-
associated traits. Furthermore, the number of cancer cells in different ROI need to be evaluated for 
a fair comparison,, i.e., a particular ROI can be less inflamed. This confusion could be at least 
partially resolved if the infiltration could be quantified on the tumor islets level and the EMT status 
determined for single cancer cells instead of for the bulk population. For example, Seo et al. stained 
both EMT and CD8 markers for one breast cancer patient and found a positive correlation between 
the two [200]. However, the markers were not on the same section and there is still an issue of 
defining the immune infiltration. Therefore, it would be ideal to study the gene expression/protein 
abundance of the tumor islets or the sorted tumor cells in addition to the analysis of the 
corresponding images of the same tumor, so that we can have a better idea about whether there is 
any association between the EMT status of cancer cells and the infiltration of cancer-killing 
immune cells into the tumor islets. 
 
Causal relationship between EMT and infiltration of cancer-killing immune cells 
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Even if we overcome the above-mentioned issues regarding the correlation between EMT and the 
infiltration of cancer-killing immune cells, there is still a hard problem to understand the causal 
relationship between the two. There is here an issue of the temporal coevolution of the tumor 
microenvironment which could play a role. Specifically, it is possible that apparently contradictory 
observations are in fact different snapshots of the co-evolution process of the two sets of cells. We 
can propose two potential scenarios on the causal relationship between the EMT status of cancer 
cells and the polarity of the immune microenvironment as well as the infiltration of cancer-killing 
immune cells. 
 
The first scenario: tumor regions enriched with epithelial cancer cells first attract cancer-killing 
immune cells and then cancer cells are attacked by these immune cells. If one investigates the 
infiltration of immune cells at this stage, these epithelial tumors should be enriched by cancer-
killing immune cells. The immune attack may convert epithelial-like cancer cells into 
mesenchymal-like ones [187]. Then the mesenchymal-like cancer cells can suppress the function 
of cancer-killing immune cells and start to promote the accumulation of immune-suppressing 
immune cells. Following this logic, at this stage, the mesenchymal-enriched tumors regions should 
have the infiltration of both cancer-killing and immune-suppressing immune cells. The TCGA data 
analysis results seem to support this hypothesis [190–192]. However, many in vivo experiments 
do not seem to support the late stage assumption of this scenario [172,189] even though 
experiments using epithelial-like cancer cell lines tend to support the early state aspects of this 
scenario at the early state [173]. 
 
The second scenario: before the engagement of immune systems, the cancer cells interact mainly 
with the cancer-associated fibroblasts (CAFs) or the tumor-associated macrophages (TAMs). The 
paracrine signaling between the two (cancer cells and CAFs, or cancer cells and TAMs) biases the 
cancer cells towards mesenchymal-like phenotypes [174–176]. Consequently, those 
mesenchymal-like cancer cells tend to exclude cancer-killing immune cells from the 
microenvironment. This exclusion may be also due to the accumulation of TAMs [188] or the 
absence of specific types of dendritic cells [189]. In addition, the mesenchymal-like cancer cells 
may also have their own ways to stop or exclude cancer-killing T cells [178,179,182]. In this 
scenario, epithelial tumors that do not undergo EMT (due to interactions with CAFs or TAMs) 
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may be infiltrated by cancer-killing immune cells whereas mesenchymal tumors tend to exclude 
cancer-killing immune cells. Apparently, this scenario seems to be supported by the in vitro co-
culture experiments as well as some in vivo studies but is not supported by most TCGA data 
analyses results. 
 
In order to test different scenarios, it will be essential to monitor the trajectory of EMT of cancer 
cells as well as the evolution of the infiltration of cancer-killing immune cells in a single mouse. 
It has been shown that even in a single mouse model, some tumors can be “hot”, and others can be 
“cold” [201]. The particular mouse model used in this recent study can be an ideal system to study 
the co-evolution of the EMT status of cancer cells as well as the infiltration pattern of cancer-
killing immune cells to better understand the causal relationship between the two. 
 
Hybrid E/M phenotypes and beyond  
Our claim here has been that hybrid E/M phenotypes enable cancer cells metastatic plasticity to 
effectively metastasize. Notably, such stable hybrid phenotypes that combines features of two 
speciously exclusive phenotypes is not limited to EMT. For example, during pathological 
angiogenesis in cancer, a stable hybrid tip/stalk phenotype that results in poorly perfused and 
chaotic angiogenesis can be acquired due to the overexpressed Jagged [202]. The elevated 
production of Jagged in cancer can also promote the existence of a stable hybrid sender/receiver 
state where cells maintain intermediate levels of Jagged and Delta (ligands) and Notch (receptor) 
thus allowing cells the plasticity to both send and receive signals [90]. Another example of a hybrid 
phenotype in cancer appears to arise in cancer metabolic preprogramming. Some cancer cells can 
acquire a stable hybrid metabolic phenotype where both glycolysis and oxidative phosphorylation 
(OXPHOS) can be utilized [203–205]. Such hybrid metabolic phenotype enables cancer cell 
metabolic plasticity to grow and prosper in various hostile microenvironments. The hybrid 
metabolic phenotype has been observed in the human TNBC SUM159-PT and MDA-MB-231 and 
mouse breast cancer 4T1 cells at least at a population level. The emergence of the hybrid metabolic 
phenotype indicates that targeting both glycolysis and OXPHOS may be necessary to eliminate 
cancer metabolic plasticity. Notably, such a hybrid metabolic phenotype is not limited to cancer 
cells. For example, the naive pluripotent stem cells (PSCs) exhibit a hybrid glycolysis/OXPHOS 
phenotype relative to primed PSCs which primarily use glycolysis and somatic cells which 
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primarily use OXPHOS [206]. As a result, activation of both OXPHOS and glycolysis, 
synergistically by the TFs Zic3 and Esrrb for example, is essential to reprogram somatic cells to 
acquire the naive pluripotency. In addition, regulatory T cells that utilize both glycolysis and fatty 
acid oxidation can be more effective in expansion than those that primarily use glycolysis [207]. 
In our final example, the T-helper (Th) cells can acquire a stable hybrid Th1/Th2 phenotype where 
cells co-express two mutually inhibiting TFs T-bet (stimulating Th1) and GATA3 (stimulating 
Th2) [208]. The hybrid Th1/Th2 phenotype combines the properties of Th1 and Th2 and can 
regulate effector T cell to function without excessive inflammation. In summary, it is reasonable 
to speculate that the hybrid phenotype is a common characteristic emerging from cellular 
plasticity.   
 
Conclusions and Future Vision 
Epithelial-mesenchymal plasticity has attracted much attention due to its critical roles in 
facilitating metastases, stemness and immune repression. Emerging evidence suggests that cancer 
cells can acquire a spectrum of hybrid E/M phenotypes and cells can transition back and forth 
between different EMT phenotypes. Computational and experimental studies have been combined 
to deepen our understanding of EMT dynamics, the emergence of hybrid E/M phenotypes and the 
interplay of EMT with stemness and immune suppression. Notably, EMT is a multi-dimensional 
spatiotemporal program including alterations in mRNA and protein abundance, protein 
modification and relocation which can mediate the changes in cell junction, morphology and 
apico-basal polarity, resulting in adoption of cell migratory and invasive properties. Future 
computational studies need to integrate different facets of EMT to systemically elucidate EMT 
dynamics and quantify EMT status. The advance in experimental technologies such as 
simultaneous measurement of transcriptome and proteome at a single-cell level - CITE-seq [209] 
and REAP-seq [210], intravital correlative microscopy [211] will contribute to high-resolution 
quantification of EMT in vivo. The combination of theoretical and experimental efforts will 
continue uncovering important mechanisms underlying epithelial-mesenchymal plasticity and its 
association with other hallmarks of cancer. 
 
Thus, the emergence of hybrid phenotypes in cancer and the ability of cancer cells to switch back 
and forth between various phenotypes indicate that therapeutic strategies targeting cancer cell 
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plasticity needs to be designed more carefully. Eliminating the notoriously aggressive hybrid 
phenotypes in cancer may serve as the first step towards conquering cancer. 
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